RGLS 241220 1.00C (RGLS241220C1000) Stock Options, News & Quotes

US OptionsDetailed Quotes

RGLS241220C1000

Watchlist

0.78
+0.20+34.48%

15min DelayClose Nov 22 16:00 ET

0.78High0.78Low

Intraday

5D
Daily

News

Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsNov 12 08:31 ET · Ratings
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
TipRanksNov 11 06:37 ET · Ratings
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
TipRanksNov 11 01:26 ET · Ratings
Regulus Therapeutics GAAP EPS of -$0.21 Misses by $0.04
Seeking AlphaNov 7 18:11 ET
Regulus Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 7 16:33 ET · Announcements
Regulus Therapeutics | 8-K: Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
SECNov 7 16:22 ET

Comments

Stock_Drift

Oct 24 15:16

After Hours Ticks. 4:15pm

$Visionary Holdings (GV.US)$ $Western Digital (WDC.US)$ $Integrated Media Technology (IMTE.US)$ $Deckers Outdoor (DECK.US)$ $MediaCo (MDIA.US)$ $Skechers USA (SKX.US)$ $Regulus Therapeutics (RGLS.US)$ $Abits (ABTS.US)$ $Spark I Acquisition Corporation (SPKL.US)$ $Tapestry (TPR.US)$ $Antelope Enterprise (AEHL.US)$ $Jeffs' Brands (JFBR.US)$ $Lyell Immunopharma (LYEL.US)$ $Smart Powerr (CREG.US)$ $Bionomics (BNOX.US)$
📊⚡️📊

Trytosaveabit

Oct 8 07:03

Update

$Regulus Therapeutics (RGLS.US)$ Regulus Therapeutics Inc: Remain on Track for an End of Phase 1 Meeting With FDA by End of 2024

Jaguar8

Oct 8 07:02

NEWS

$Regulus Therapeutics (RGLS.US)$
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dragana

Sep 12 21:46

$Regulus Therapeutics (RGLS.US)$ is ready Almost there.🙌

Ultratech

Sep 12 20:46

$Regulus Therapeutics (RGLS.US)$
Vanguard loaded